Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
14
datasets available to search
ShareScore release 0.9.0
Dataset results
14 results for “Heterologous booster”
A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
ClinicalTrials.gov study NCT05299359. IPD Sharing: YES. Countries: 1. Publications: 2.
Safety and immunogenicity of heterologous booster immunization with Ad5-nCoV after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults: a randomized, double-blind, parallel-controlled trial
<p>Data on safety and immunity of heterologous booster (fourth dose) after three-dose priming with inactivated SARS-CoV-2 vaccine are limited in Chinese adults. Here, we evaluate the safety and immunogenicity of immunization with Ad5-nCoV in a randomized, double-blind, parallel-controlled phase 4 clinical trial in Zhejiang, China (NCT05373030). Participants aged 18-80 years (100 participants per group) who have administered three doses of inactivated SARS-CoV-2 vaccine ≥ 6-month earlier were enrolled and randomized at 1:1 into two groups, then administered intramuscular Ad5-nCoV or different inactivated SARS-CoV-2 vaccine (CoronaVac or Covilo) respectively. All observed adverse reactions were predictable and manageable. Ad5-nCoV elicited significantly higher RBD-specific IgG levels, with a GMC of 2924.0 on day 14 post-booster, 7.8-fold that of the inactivated vaccine. Pseudovirus-neutralizing antibodies to Omicron BA.4/5 showed a similar pattern, with GMT of 228.9 in the Ad5-nCoV group and 65.5 in the inactivated vaccine group. The Ad5-nCoV booster-maintained a high antibody levels on day 90, with seroconversion of 71.4%, while the inactivated vaccine group was 5.2%, closed to pre-booster levels. In summary, a fourth Ad5-nCoV vaccination following three-dose inactivated SARS-CoV-2 vaccination is immunogenic, tolerable, and more efficient than inactivated SARS-CoV-2 vaccine. Ad5-nCoV elicits a stronger humoral response against Omicron BA.4/5 and maintains antibody levels for longer than homologous boosting.</p>
Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine
ClinicalTrials.gov study NCT05109559. IPD Sharing: NO. Countries: 1. Publications: 2.
Database of Study SARS-CoV-2 Antibody Level after Homologous and Heterologous Booster Vaccines an 18-month Longitudinal Observational Cohort Study in Indonesia (Ardyanto et el., 2024)
Open the record for dataset details and reuse information.
An open heterologous booster database for COVID-19 vaccines
<p>The development and deployment of vaccines have played a critical role in the control and management of the COVID-19 pandemic. Although homologous vaccination regimens (i.e. vaccinations where individuals received both prime and boost from the same commercial source) were widely administered, many recent studies have shown improved protection from mix-and-match heterologous prime-boost strategies. While most ongoing studies or clinical trials only focus on single or a limited number of heterologous prime-boost regimens, the general landscape of heterologous boosting is not well established. To better study this, the OpenData Portal (ODP) team at the National Center for Advancing Translational Sciences (NCATS) is building an open database for heterologous boost data which actively tracks the clinically tested and varied heterologous vaccination strategies. Preprints and peer-reviewed publications were curated to aggregate <em>in vitro</em> activity data and metadata pertaining to homologous and heterologous vaccine regimens. This database will allow users to investigate the reported <em>in vitro</em> effectiveness of heterologous boosters compared to corresponding homologous boosters. Our efforts to establish the open heterologous boost database aims to provide a high-level overview of current heterologous boosting studies and contribute to the improvement of vaccination strategies for COVID-19 and other pathogens of pandemic potential in the future.</p>
Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
<p>The recent emergence of the Omicron variant has raised concerns on vaccine efficacy and the urgent need to study more efficient vaccination strategies. Here we evaluated the effect of an mRNA vaccine booster on immunogenicity in individuals vaccinated with two doses of inactivated vaccine. We observed that an mRNA vaccine booster significantly increased the plasma level of specific antibodies that bind to the receptor-binding domain (RBD) or the spike (S) ectodomain (S1+S2) of both the G614 and the Omicron variants, compared to two doses of homologous inactivated vaccine. The level of RBD- and S-specific IgG antibodies and virus neutralization titers against variants of concern in the heterologous vaccination group were similar to that in individuals receiving three doses of homologous mRNA vaccine or a boost of mRNA vaccine after infection, but markedly higher than that in individuals receiving three doses of a homologous inactivated vaccine. Moreover, this heterologous vaccination regime significantly enhanced the RBD-specific memory B cell response and S1-specific T cell response compared to two or three doses of homologous inactivated vaccine. Our study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can be highly beneficial, as it markedly increases the humoral and cellular immune responses against the virus, including the Omicron variant</p>
Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination
ClinicalTrials.gov study NCT05545683. IPD Sharing: NO. Countries: 1. Publications: 0.
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
ClinicalTrials.gov study NCT05501522. IPD Sharing: NO. Countries: 2. Publications: 0.
Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad
ClinicalTrials.gov study NCT05428592. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age
ClinicalTrials.gov study NCT05727215. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
ClinicalTrials.gov study NCT05928455. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
ClinicalTrials.gov study NCT05492643. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
ClinicalTrials.gov study NCT05175950. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
ClinicalTrials.gov study NCT05928468. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.